Description

1,3-Dihydro-1-Methyl-7-(n-Methylmethylsulfonylamino)-5-Phenyl-2H-1,4-Benzodiazepin-2-One CAS NO 33211-51-7 is a high-purity, specialized benzodiazepine derivative of significant interest in advanced pharmaceutical research and development. This compound serves as a critical pharmaceutical intermediate or reference standard for the synthesis and study of novel therapeutic agents targeting the central nervous system. It is primarily required by pharmaceutical R&D laboratories, contract research organizations (CROs), and manufacturers of active pharmaceutical ingredients (APIs) focused on neurological and psychiatric drug discovery.

Application

• Pharmaceutical Intermediate: A key building block in the multi-step synthesis of novel benzodiazepine-based active pharmaceutical ingredients (APIs).
• Reference Standard: Used for analytical method development, validation, and quality control in pharmaceutical manufacturing to ensure product identity and purity.
• Medicinal Chemistry Research: A crucial scaffold for structure-activity relationship (SAR) studies aimed at developing new therapeutic agents with optimized efficacy and safety profiles.
• Preclinical Drug Development: Employed in the synthesis of candidate compounds for pharmacological screening, toxicology studies, and pharmacokinetic evaluation.
• Academic Research: Utilized in university and institutional laboratories for studying benzodiazepine receptor interactions and related neurochemical pathways.
• Custom Synthesis: Serves as a starting material for the contract synthesis of specialized, non-commercial analogs for targeted research programs.

Basic Information

Product Name	1,3-Dihydro-1-Methyl-7-(n-Methylmethylsulfonylamino)-5-Phenyl-2H-1,4-Benzodiazepin-2-One
CAS No.	33211-51-7
Molecular Formula	C19H21N3O3S
Molecular Weight	371.45 g/mol
Synonyms	7-[(Methylsulfonyl)(methyl)amino]-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 1-Methyl-7-[(methylsulfonyl)(methyl)amino]-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-(N-Methylmethanesulfonamido)-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; Ro 07-9749; Ro 07-9749/000; Ro 07-9749/001; Benzodiazepin-2-one derivative (33211-51-7)
EINECS	Contact for details

Quality Control

Our production of 1,3-Dihydro-1-Methyl-7-(n-Methylmethylsulfonylamino)-5-Phenyl-2H-1,4-Benzodiazepin-2-One adheres to stringent quality management protocols. The material is manufactured and controlled to meet the exacting standards required for pharmaceutical research applications. Certificates of Analysis (COA) are provided with each batch, detailing identity, purity, and impurity profiles as determined by advanced analytical techniques including HPLC, NMR, and mass spectrometry.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated place. Due to its hygroscopic nature, the container must be kept tightly sealed under dry, inert conditions to prevent moisture absorption. Recommended long-term storage temperature is 2-8°C (refrigerated). Allow the sealed container to reach room temperature before opening to minimize condensation.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single impurity ≤ 1.0%
Loss on Drying	≤ 0.5%
Residue on Ignition	≤ 0.1%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.